Micro Medical Solutions

Micro Medical Solutions (MMS), established in 2014 by Gregory Sullivan, is a medical device company focused on developing minimally invasive solutions for microvascular intervention. The company directs its efforts toward addressing the high rate of amputation in patients with peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI), a severe manifestation of PAD.

The company's core technology is the MicroStent, a vascular stent specifically engineered for arteries below the knee. This self-expanding nitinol stent features a 48-strand, closed-cell braided design with a platinum core for enhanced visibility during procedures. Its construction is intended to provide flexibility, adapt to the vessel's path, and resist kinking, even in highly calcified arteries. The MicroStent is part of a broader Micro Vascular Integrated Platform (mVIP) that also includes the MicroBalloon and MicroGuide, which have received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

MMS serves interventional cardiologists, vascular surgeons, and other physicians who treat PAD and CLTI. The company's business model centers on the development, clinical validation, and commercialization of its medical devices. Since its founding, MMS has secured approximately $13 million in funding over nine rounds, including debt and equity financing, to support research, development, and extensive clinical trials. Key milestones include receiving CE Mark approval for the MicroStent in Europe, which allowed for its commercial use in several EU countries. In May 2021, the FDA granted the MicroStent Breakthrough Device Designation, a status intended to expedite the development and review of technologies for life-threatening conditions. The company has been actively engaged in multiple clinical studies, including the STAND pivotal trial in the U.S. and the HEAL observational study in Europe, to gather data on the device's safety and effectiveness. In July 2025, a strategic leadership transition was announced, with founder Gregory Sullivan moving to the Chief Technology Officer role and George Quinoy, a seasoned executive with experience at Medtronic and Guidant, appointed as President and CEO to steer the company through its next phase of commercialization. Keywords: MicroStent, peripheral artery disease, chronic limb-threatening ischemia, below-the-knee intervention, microvascular intervention, vascular stent, amputation prevention, endovascular treatment, Gregory Sullivan, George Quinoy, MedTech, vascular devices, CLI treatment, PAD treatment, interventional cardiology, limb salvage, nitinol stent, medical device, micro-scaffolding, CE Mark, FDA Breakthrough Device